194 related articles for article (PubMed ID: 16824641)
1. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-study.
Jommi C; Paruzzolo S
Health Policy; 2007 Apr; 81(1):117-30. PubMed ID: 16824641
[TBL] [Abstract][Full Text] [Related]
2. Australia's bio-regulatory framework: leading the way for stem cell research.
Hill H
J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
[TBL] [Abstract][Full Text] [Related]
3. Market entry and exit by biotech and device companies funded by venture capital.
Burns LR; Housman MG; Robinson CA
Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
Garattini L; Cornago D; De Compadri P
Health Policy; 2007 Aug; 82(3):330-9. PubMed ID: 17125881
[TBL] [Abstract][Full Text] [Related]
5. Enabling Europe to innovate.
Dearing A
Science; 2007 Jan; 315(5810):344-7. PubMed ID: 17234939
[TBL] [Abstract][Full Text] [Related]
6. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
7. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
8. Indian Biotech Bazaar: a swot analysis.
Kumar A
Biotechnol J; 2007 May; 2(5):543-5. PubMed ID: 17479978
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical companies and Italian Regional Governments: managing relationships in an increasing institutional complexity.
Compagni A; Cavalli L; Jommi C
Health Policy; 2008 Sep; 87(3):333-41. PubMed ID: 18384907
[TBL] [Abstract][Full Text] [Related]
10. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs.
Kang KN; Lee YS
Biotechnol Lett; 2008 Oct; 30(10):1699-704. PubMed ID: 18506395
[TBL] [Abstract][Full Text] [Related]
11. Rebuilding the R&D engine in big pharma.
Garnier JP
Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
[TBL] [Abstract][Full Text] [Related]
12. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
Kettler HE; Modi R
Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. [Cost reductions and their effects on drug research].
Götte D
Med Klin (Munich); 2005 Jun; 100(6):309-13. PubMed ID: 15968482
[TBL] [Abstract][Full Text] [Related]
15. Influence of organizational characteristics and context on research utilization.
Cummings GG; Estabrooks CA; Midodzi WK; Wallin L; Hayduk L
Nurs Res; 2007; 56(4 Suppl):S24-39. PubMed ID: 17625471
[TBL] [Abstract][Full Text] [Related]
16. A review of regulatory decisions for environmental protection: part II - the case-study of contaminated land management in Portugal.
Rodrigues SM; Pereira ME; da Silva EF; Hursthouse AS; Duarte AC
Environ Int; 2009 Jan; 35(1):214-25. PubMed ID: 18835040
[TBL] [Abstract][Full Text] [Related]
17. Substance abuse prevention infrastructure: a survey-based study of the organizational structure and function of the D.A.R.E. program.
Merrill JC; Pinsky I; Killeya-Jones LA; Sloboda Z; Dilascio T
Subst Abuse Treat Prev Policy; 2006 Sep; 1():25. PubMed ID: 16956400
[TBL] [Abstract][Full Text] [Related]
18. European research infrastructures for the development of nanobiotechnologies.
Péro H; Faure JE
Trends Biotechnol; 2007 May; 25(5):191-4. PubMed ID: 17368840
[TBL] [Abstract][Full Text] [Related]
19. The cost of Latin American science Introduction for the second issue of CBP-Latin America.
Zenteno-Savín T; Beleboni RO; Hermes-Lima M
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):463-9. PubMed ID: 16962348
[TBL] [Abstract][Full Text] [Related]
20. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
Gruber AC
Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
